BSH 2023 | The changing landscape of BTK inhibitor therapy in patients with MZL

Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, comments on the changing landscape of Bruton’s tyrosine kinase (BTK) inhibitor therapy for patients with marginal zone lymphoma (MZL). Dr Linton explains that patients undergoing treatment with first-generation BTK inhibitors often require dose adjustments and can experience dose-limiting toxicities, emphasizing the value of more selective second-generation BTK inhibitors, such as zanubrutinib. Dr Linton concludes with a brief explanation of the IELSG48 randomized trial, which will compare rituximab monotherapy with rituximab plus zanubrutinib combination therapy in patients with newly diagnosed splenic MZL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.